Trial Profile
Efficacy of tyrosine-kinase inhibitors (sunitinib or sorafenib) in patients with papillary type II renal cell carcinoma or clear cell renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 17 Dec 2015 New trial record